Innobioscience SpA   Report issue

For profit Phase 2
Founded: Bradenton FL United States (2013)
Status: Left NME R&D (2016)

Organization Overview

First Clinical Trial
2014
NCT02273635
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

andrographolide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1